Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Accelerated neuro-retinal thinning in Alzheimer’s disease reflects cognitive decline: a longitudinal study
Aging, Dementia, and Behavioral Neurology
P9 - Poster Session 9 (12:00 PM-1:00 PM)
10-001
To explore the value of optical coherence tomography (OCT) in monitoring people with Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI)
Several cross-sectional studies showed significant reduction of neuro-retina thickness in AD. To our knowledge, longitudinal studies investigating neuro-retina thinning rates over time in AD and possible correlations with disease progression are still lacking
52 patients (23 AD and 29 MCI) were prospectively enrolled and compared with 16 cognitively unimpaired control subjects (CS). They underwent measurement of peripapillary Retinal Nerve Fiber Layer (RNFL) thickness and macular Ganglion Cell Layer's (GCL and IPL) volume at baseline and at a mean follow up at 2.34 (±1.6 SD) years. Baseline Cerebrospinal Fluid (CSF) AD biomarkers (Aβ42, t-tau and p-tau) and baseline and follow-up neuropsychological tests were available in 19 AD and 25 MCI. One way ANCOVA with age, sex and baseline OCT measures as covariates was used to compare thinning rates among groups. 

AD patients showed a significantly higher year thinning rate of RNFL overall thickness [mean (95%C.I.)] than CS: -1.66 (- 2.86; - 0.47) vs -0.62 ± (- 1.48; 0.23) μm, p= 0.037. Considering the RNFL thickness in the superior quadrant, AD showed higher thinning rates than both CS: -3.57 (- 6; - 1.1) vs 0.07 ± (- 1.5; 1.6) μm, p= 0.001 and MCI: -1.28 (- 2.21; - 0.35) μm, p=0.01. GCL thinning was faster in MCI with abnormal vs normal CSF biomarkers: -0.018 (- 0.03; - 0.002) vs 0.009 ± (- 0.007; 0.03) mm3, p=0.032. Finally, GCL thinning was associated with cognitive worsening over time in memory (Pearson r=0.579, p= 0.03) and MMSE (Pearson r=0.384, p= 0.048).

The finding of an association between neuroretinal thinning and cognitive decline over time prompts further studies to validate OCT as cost effective, objective and easy to handle method to monitor neurodegeneration in AD
Authors/Disclosures
Roberto Santangelo
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Monica Falautano (Ospedale San Raffaele) Monica Falautano has nothing to disclose.
Massimo Filippi, MD, FÂ鶹´«Ã½Ó³»­ (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Giancarlo Comi, MD (University Vita-Salute) Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind.
Giuseppe Magnani Giuseppe Magnani has nothing to disclose.
Letizia M. Leocani, MD (University Vita-Salute San Raffaele, INSPE) Dr. Leocani has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche . Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Leocani has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Med-ex learning.